On May 19, 2021 EXACT THERAPEUTICS AS ("EXACT-Tx" or the "Company"), a clinical stage precision medicine company utilizing Acoustic Cluster Therapy (ACT) across multiple therapeutic areas, reported that it has been granted a patent for its innovative Acoustic Cluster Therapy technology in Japan (Press release, Exact Therapeutics, MAY 19, 2021, View Source [SID1234580357]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent covers EXACT-Tx`s unique microbubble/microdroplet formulation and its use, co-administered with a range of pharmaceutical agents for ultrasound mediated therapeutic targeting.

"We are delighted with the decision of the Japanese Patent Office in granting this important patent for ACT, which complements the existing patent granted in China in November 2019. This core patent represents the foundation of our dynamic IP strategy, which encompasses the use of ACT with a variety of therapeutics across a multitude of indications",

said Dr Rafiq Hasan, CEO of EXACT Therapeutics AS.